您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 心血管系统药物->心肌梗死
处方药:处方药
包装规格: 50毫克
计价单位:
  点击放大  
生产厂家英文名:
Genentech, Inc.
该药品相关信息网址1:
https://www.tnkase.com/
原产地英文商品名:
TNKase 50mg Powder For Injection
原产地英文药品名:
tenecteplase
中文参考商品译名:
TNKase 50毫克 注射用粉末
中文参考药品译名:
替奈普酶
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
in the reduction of mortality associated with acute myocardial infarction (AMI)
临床试验期:
完成
中文适应病症参考翻译1:
降低与急性心肌梗死(AMI)相关的死亡率
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201991710254533.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文TNKase处方资料(仅供参考)

【英文名称】TNKase

【适用证】

TNKase(替奈普酶)适用于降低与急性心肌梗死(AMI)相关的死亡率。 AMI症状出现后应尽快开始治疗(见临床研究)

【用法用量】

TNKase(替奈普酶)仅用于静脉内给药。 建议的总剂量不应超过50毫克,并以患者体重为基础。

单次推注剂量应根据患者体重在5秒内给药。 AMI症状发作后应尽快开始治疗(见临床研究)。

患者体重(kg); TNKas e(mg);给药量TNKas(mL)

<60; 30; 6

≥60至<70; 35; 7

≥70至<80; 40; 8

≥80至<90; 45; 9

≥90; 50; 10

仅在临床研究中描述的同时施用肝素和阿司匹林的情况下研究了TNKase的安全性和有效性。

【禁忌】

对于急性心肌梗死患者的TNKas e疗法在以下情况下是禁忌的,因为出血风险增加(警告):

---主动内出血

---脑血管事故史

--- 2个月内颅内或脊柱内手术或创伤

---颅内肿瘤,动静脉畸形或动脉瘤

---已知的出血素质

---严重不受控制的高血压

【INDICATIONS】

TNKase (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms (see CLINICAL STUDIE

【DOSAGE】

TNKase (Tenecteplase) is for intravenous administration only. The recommended total dose should not exceed 50 mg and is based upon patient weight.

A single bolus dose should be administered over 5 seconds based on patient weight. Treatment should be initiated as soon as possible after the onset of AMI symptoms (see CLINICAL STUDIES).

Patient Weight (kg); TNKas e(mg); Volume TNKas e to be administered (mL)

<60; 30; 6

≥60 to <70; 35; 7

≥70 to <80; 40; 8

≥80 to <90; 45; 9

≥90; 50; 10

The safety and efficacy of TNKase have only been investigated with concomitant administration of heparin and aspirin as described in CLINICAL STUDIES.

【CONTRAINDICATIONS】

TNKas e therapy in patients with acute myocardial infarction is contraindicated in the following situations becaus e of an increas ed risk of bleeding (s ee WARNINGS):

---Active internal bleeding

---History of cerebrovas cular accident

---Intracranial or intraspinal surgery or trauma within 2 months

---Intracranial neoplasm, arteriovenous malformation, or aneurysm

---Known bleeding diathesis

---Severe uncontrolled hypertens

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201991710254533.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2019-09-16
附件:
201991710254533.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com